This study identified the clusters with MTAP/CDKN2A-altered and MTAP/CDKN2A-unaltered groups with distinct levels of genomic alteration, clinicopathological features, and immune infiltration in patients with RCC. This evidence concerns the gene CDKN2A and renal cell carcinoma.